ketankumar patel

Dr. ketankumar patel

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SPSiddhant Palekar
Siddhant Palekar
PNPavan Kumar Nukala
Pavan Kumar Nukala
SMSaurabh M Mishra
Saurabh M Mishra
TKThomas Kipping
Thomas Kipping
KPketankumar patel
ketankumar patel

23 July 2020 in Nanomedicine
Verified
Journal Article
Closed access
ASAishwarya Saraswat
Aishwarya Saraswat
MPManali Patki
Manali Patki
YFYige Fu
Yige Fu
SBShrikant Barot
Shrikant Barot
VDVikas V Dukhande
Vikas V Dukhande
KPketankumar patel
ketankumar patel
Aim: To explore the anticancer activity of a novel BRD4 protein degrader ARV-825 (ARV) and its nanoformulation development (ARV-NP) for treatment of pancreatic cancer. Materials & methods: ARV-NP w... Graphical abstract

29 September 2022 in Drug Discovery Today
Verified
Journal Article
Closed access
ASAishwarya L. Saraswat
Aishwarya L. Saraswat
RVRicha Vartak
Richa Vartak
RHRehab Hegazy
Rehab Hegazy
APAkanksha Patel
Akanksha Patel
KPketankumar patel
ketankumar patel

15 January 2019 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
PNPavan Kumar Nukala
Pavan Kumar Nukala
SPSiddhant Palekar
Siddhant Palekar
MPManali Patki
Manali Patki
KPketankumar patel
ketankumar patel

1 May 2020 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
RVRicha Vartak
Richa Vartak
SMSuvidha Menon
Suvidha Menon
MPManali Patki
Manali Patki
BBBlase Billack
Blase Billack
KPketankumar patel
ketankumar patel

13 May 2021 in Nanomedicine
Verified
Journal Article
Closed access
RVRicha Vartak
Richa Vartak
SPSuyash M Patil
Suyash M Patil
ASAishwarya Saraswat
Aishwarya Saraswat
MPManali Patki
Manali Patki
Nitesh KundaNitesh Kunda
Nitesh Kunda
KPketankumar patel
ketankumar patel
Aim: To formulate an aerosolized nanoliposomal carrier for remdesivir (AL-Rem) against coronavirus disease 2019. Methods: AL-Rem was prepared using modified hydration technique. Cytotoxicity in lun... Graphical abstract Lay abstract Remdesivir is one of the first drugs approved for the treatment of coronavirus disease 2019. Currently, it is administered via an injection into the bloodstream. This means that the dr...